Literature DB >> 21380940

Effects of combination lipid therapy in diabetes mellitus.

John A Farmer1.   

Abstract

Entities:  

Year:  2011        PMID： 21380940     DOI： 10.1007/s11883-011-0162-7

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


× No keyword cloud information.
  7 in total

1.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

Authors:  M H Frick; O Elo; K Haapa; O P Heinonen; P Heinsalmi; P Helo; J K Huttunen; P Kaitaniemi; P Koskinen; V Manninen
Journal:  N Engl J Med       Date:  1987-11-12       Impact factor: 91.245

Review 2.  Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

Authors:  Min Jun; Celine Foote; Jicheng Lv; Bruce Neal; Anushka Patel; Stephen J Nicholls; Diederick E Grobbee; Alan Cass; John Chalmers; Vlado Perkovic
Journal:  Lancet       Date:  2010-05-10       Impact factor: 79.321

3.  Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

Authors:  Hanna Bloomfield Rubins; Sander J Robins; Dorothea Collins; David B Nelson; Marshall B Elam; Ernst J Schaefer; Fred H Faas; James W Anderson
Journal:  Arch Intern Med       Date:  2002 Dec 9-23

4.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Authors:  A Keech; R J Simes; P Barter; J Best; R Scott; M R Taskinen; P Forder; A Pillai; T Davis; P Glasziou; P Drury; Y A Kesäniemi; D Sullivan; D Hunt; P Colman; M d'Emden; M Whiting; C Ehnholm; M Laakso
Journal:  Lancet       Date:  2005-11-26       Impact factor: 79.321

5.  Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.

Authors: 
Journal:  Lancet       Date:  2001-03-24       Impact factor: 79.321

6.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

Authors:  S M Haffner; S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

7.  Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Authors:  Russell Scott; Richard O'Brien; Greg Fulcher; Chris Pardy; Michael D'Emden; Dana Tse; Marja-Riitta Taskinen; Christian Ehnholm; Anthony Keech
Journal:  Diabetes Care       Date:  2008-11-04       Impact factor: 19.112
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.